BSECompany Update22 Jun 2026 · 22 Jun 2026, 04:40 pm
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
Bafna Pharmaceuticals Ltd · 532989
✦ AI SummaryMgmt Change
Bafna Pharmaceuticals Ltd announced the retirement of Mr. Navin Kumar, an Independent Director, upon completing his first term effective June 22, 2026. Consequently, he will also cease to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has reconstituted these committees to ensure continued compliance with regulatory requirements, affirming that the board composition remains compliant.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bafna Pharmaceuticals Ltd - 532989 - Announcement under Regulation 30 (LODR)-Change in Directorate
Attachments (1)
📄pdf
Download →
4c282fe1-de56-4238-afc6-5591bf17b577.pdf
View document text
BAFNA PHARMACEUTICALS LIMITED
REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698
Date: June 22, 2026
BSE Limited, National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers, Exchange Plaza,
Dalal Street, Bandra Kurla Complex,
Mumbai - 400001. Bandra East, Mumbai – 400051.
Scrip Code: 532989 Scrip Code: BAFNAPH
Dear Sir/Madam,
Subject: Disclosure Pursuant to Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 – Retirement of Independent
Director of the Company
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that
Mr. Navin Kumar (DIN: 08778662) will be retiring as an Independent Director of the
Company upon completion of his first term, with effect from close of business hours on June
22, 2026. Consequently, he will also cease to be the Chairman of the Audit Committee and
the Nomination & Remuneration Committee of the Company.
Further, we wish to inform you that due to the aforesaid change in composition of the Board
of Directors, the following Committees of the Board of Directors have been re-constituted
with effect from June 23, 2026, as detailed below:
Name of the Name of the Director Designation & Category
Committee
Mr. Palamadai Krishnan Chairman (Non-Executive, Independent)
Sundaresan
Mrs. Ravichandran Chitra Member (Non-Executive, Independent)
Audit Committee
Mr. Upendar Mekala Reddy Member (Non-Executive, Non-
Independent)
Mr. Palamadai Krishnan Chairman (Non-Executive, Independent)
Sundaresan
Nomination and
Mrs. Ravichandran Chitra Member (Non-Executive, Independent)
Remuneration
Committee
Mrs. Akila Chintalapati Raju Member (Non-Executive, Non-
Independent)
Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com
BAFNA PHARMACEUTICALS LIMITED
REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698
Notwithstanding the aforesaid retirement of the Independent Director, the composition of the
Board and its Committees continues to remain in compliance with the requirements of the
applicable laws.
The disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read
with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January
30, 2026, is enclosed as Annexure.
We request you take the above information on record.
Thanking You.
For BAFNA PHARMACEUTICALS LIMITED
Mohanachandran A
Company Secretary & Compliance Officer
Enclosed: As Above
Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com
BAFNA PHARMACEUTICALS LIMITED
REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698
Annexure
Disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015
read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026
dated January 30, 2026 as under:
Sl. No. Particulars Description
1 Name of Director Mr. Navin Kumar
2 DIN 08778662
3 Reason for change Retirement of Mr. Navin Kumar, as an
Independent Director of the Company, upon
completion of first term, with effect from June
22, 2026.
4 Date of Cessation Close of Business Hours on June 22, 2026.
5 Brief Profile (in case of Not Applicable
appointment)
6 Disclosure of relationships Nil
between directors (in case of
appointment)
Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com